gip vs glp-1 The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP)
Description
Tirzepatide takes it a step further by also targeting GIP receptors, offering a dual action that provides even greater metabolic benefits
Understanding its effects establishes the baseline against which all subsequent escalations are measured
While some physicians are prescribing these medications for their approved uses of treating type 2 diabetes, obesity and obstructive sleep apnea, others are frequently making off-label prescriptions
The FDA has previously warned consumers about using compounded versions of FDA-approved medications
The absolute risk increase is more important than the relative one for individual patients
